<DOC>
	<DOCNO>NCT02573025</DOCNO>
	<brief_summary>This open-label , randomize , multi-center , single dose , two-period , two-sequence crossover study investigate bioequivalence PEG-IFN alfa-2a BA-free formulation versus reference market formulation ( PEG-IFN alfa-2a [ PegasysÂ® ] ) follow subcutaneous administration via prefilled syringe healthy Chinese participant .</brief_summary>
	<brief_title>A Bioequivalence Study Pegylated Interferon Alfa-2a ( PEG-IFN Alfa-2a ) Benzyl Alcohol ( BA ) -Free Formulation Versus PEG-IFN Alfa-2a ( Pegasys ) Following Subcutaneous Administration</brief_title>
	<detailed_description />
	<mesh_term>Benzyl Alcohol</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Healthy female male Chinese participant Body mass index 19 28 kilogram per square meter ( kg/m^2 ) , inclusive Participants determine healthy medical history , physical examination , vital sign , electrocardiogram ( ECG ) , clinical laboratory measurement perform Screening visit Female participant childbearing potential : willing use highly effective method contraception throughout study 90 day last dosing Male participant : agreement remain abstinent use spermicide barrier method contraception throughout study 90 day last dosing Able participate willing give write informed consent comply study restriction Any clinically relevant condition history cardiovascular , psychiatric , gastrointestinal , respiratory , renal , hepatic , hematological , lymphatic , neurological ( include seizure history ) , musculoskeletal , genitourinary , immunological , metabolic , malignant , dermatological disorder Participants positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( anti HCV ) human immunodeficiency virus I II antibody ( antiHIV I , antiHIV II ) test Screening Participants alanine aminotransferase ( ALT ) upper limit normal Screening Day 1 Period 1 Any condition disease ( already state ) , judgment Investigator , would place participant undue risk , interfere absorption , distribution , metabolism , excretion PEGIFN alfa2a , interfere ability participant complete study History drug alcohol abuse within last year screen Treatment interferon PEGIFN alfa2a within 3 month prior first dose Female participant pregnant , currently lactate , positive serum pregnancy test screen positive urine pregnancy test Day 1 Period 1 Use prescribe counter medication herbal medicine take within 14 day prior first dose within 5 time elimination halflife medication prior first dosing ( whichever longer ) . Exceptions paracetamol , contraceptive pill , hormone replacement therapy commonly use vitamin supplement , permit Regular smoking consumption 10 cigarette per day equivalent amount tobacco Participation investigational drug device study within 3 month prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>